A Transcriptomic-Based Tool to Predict Gemcitabine Sensitivity in Advanced Pancreatic Adenocarcinoma

Gastroenterology. 2023 Mar;164(3):476-480.e4. doi: 10.1053/j.gastro.2022.11.035. Epub 2022 Dec 7.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't
  • Letter

MeSH terms

  • Adenocarcinoma* / pathology
  • Antineoplastic Combined Chemotherapy Protocols
  • Gemcitabine
  • Humans
  • Pancreatic Neoplasms* / pathology
  • Transcriptome

Substances

  • Gemcitabine